|
Details of patients with very early inflammatory arthritis from whom follow-up synovial fluid samples were obtained in which neutrophil or lymphocyte apoptosis could be quantified |
||||||
| RA |
Non-RA |
|||||
|
|
||||||
| Persistent |
Resolving |
|||||
|
|
||||||
| Neutrophil |
Lymphocyte |
Neutrophil |
Lymphocyte |
Neutrophil |
Lymphocyte |
|
|
|
||||||
| Number of patients from whom analyzable follow-up samples were available |
10 |
7 |
11 |
11 |
11 |
13 |
| Number of analyzable follow-up samples |
16 |
12 |
25 |
26 |
17 |
21 |
| Number of weeks after symptom onset when follow-up samples were collected (median [IQR]) |
19 (15–38) |
18 (13–39) |
26 (14–46) |
28 (14–46) |
13 (9–28) |
14 (9–22) |
| Number of patients in whom more apoptosis was seen in a follow-up sample than in the initial sample |
2 |
2 |
6 |
4 |
4 |
7 |
| Treatment received prior to follow-up joint aspiration where more apoptosis was seen at follow-up |
||||||
| Nil |
0 |
1 |
1 |
0 |
0 |
1 |
| Parenteral steroid |
0 |
0 |
1 |
1 |
4 |
6 |
| DMARD |
0 |
0 |
2 |
1 |
0 |
0 |
| Parenteral steroid + DMARD |
2 |
1 |
2 |
2 |
0 |
0 |
| Treatment received prior to follow-up joint aspiration where no more apoptosis was seen at follow-up |
||||||
| Nil |
2 |
0 |
0 |
0 |
3 |
2 |
| Parenteral steroid |
1 |
0 |
4 |
6 |
4 |
4 |
| DMARD |
0 |
0 |
0 |
0 |
0 |
0 |
| Parenteral steroid + DMARD |
5 |
5 |
1 |
1 |
0 |
0 |
|
DMARD, disease-modifying antirheumatic drug; IQR, interquartile range; RA, rheumatoid arthritis. | ||||||
Raza et al. Arthritis Research & Therapy 2006 8:R120 doi:10.1186/ar2009 |
||||||